Product Portfolio & Pipeline

Product & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Marketed
ANJESO® (meloxicam) injection
ANJESO® (meloxicam) injection Preclinical complete Phase 1 complete Phase 2 complete Phase 3 complete Marketed active
Neuromuscular Blocking Agents (NMBAs)
IV intermediate-acting agent (BX-1000) Preclinical complete Phase 1 active Phase 2 not started Phase 3 not started Marketed not started
IV ultrashort-acting agent (BX-2000) Preclinical active Phase 1 not started Phase 2 not started Phase 3 not started Marketed not started
Neuromuscular Blocking Reversal
BX-3000 Preclinical active Phase 1 not started Phase 2 not started Phase 3 not started Marketed not started
Dexmedetomidine (“Dex”)
Dex-IN (intranasal) Peri-procedural pain Preclinical complete Phase 1 complete Phase 2 active Phase 3 not started Marketed not started
Dex-IN (intranasal) Cancer breakthrough pain Preclinical complete Phase 1 complete Phase 2 active Phase 3 not started Marketed not started

This information reflects public disclosures current as of August 10, 2020

Baudax Bio’s product pipeline will evolve over time as the products move through the drug development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Baudax Bio’s filings with the Securities and Exchange Commission, and actual results may vary materially. Baudax is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.